Published on 29 Apr 2024 on Simply Wall St. via Yahoo Finance
Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?
Key Insights
Using the 2 Stage Free Cash Flow to Equity, Denali Therapeutics fair value estimate is US$30.74Denali Therapeutics is estimated to be 50% undervalued based on current share price of US$15.43 Analyst price target for DNLI is US$40.27, which is 31% above our fair value estimate
How far off is Denali Therapeutics Inc. (NASDAQ:DNLI) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by estimating the company's future cash flows and discounting them to their present value. We will take advantage of the Discounted Cash Flow (DCF) model for this purpose. It may sound complicated, but actually it is quite simple!